Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations

MLA

Schuler, Martin, et al. Phase II, Open-Label Study of Erdafitinib in Adult and Adolescent Patients (Pts) with Advanced Solid Tumours Harboring Fibroblast Growth Factor Receptor (FGFR) Gene Alterations. Jan. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.unidue...bib..f591dbcf812154f4aad3603d6799b292&authtype=sso&custid=ns315887.

APA

Schuler, M., Tabernero, J., Massard, C., Iyer, G. V., Witt, O., Doi, T., Qin, S., Lu-Emerson, C., Hargrave, D., Garcia-Corbacho, J., Little, S., Xia, Q., Santiago-Walker, A., Moy, C. H., Hammond, C., Lau, Y. Y., Sweiti, H., & Pant, S. (2020). Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations.

Chicago

Schuler, Martin, J. Tabernero, C. Massard, G. Vasudeva Iyer, Olaf Witt, T. Doi, S. Qin, et al. 2020. “Phase II, Open-Label Study of Erdafitinib in Adult and Adolescent Patients (Pts) with Advanced Solid Tumours Harboring Fibroblast Growth Factor Receptor (FGFR) Gene Alterations,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.unidue...bib..f591dbcf812154f4aad3603d6799b292&authtype=sso&custid=ns315887.